An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer.
暂无分享,去创建一个
A. Abernethy | A. Finelli | A. Liede | S. Wade | R. Hernandez | D. Warner | J. Lethen
[1] F. Saad,et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. , 2016, The Lancet. Oncology.
[2] G. Scagliotti,et al. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. , 2016, Cancer treatment reviews.
[3] A. Liede,et al. Validation of International Classification of Diseases coding for bone metastases in electronic health records using technology-enabled abstraction , 2015, Clinical epidemiology.
[4] F. Saad,et al. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. , 2015, European urology.
[5] I. Tannock,et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] Neetu Chawla,et al. Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage. , 2014, Annals of epidemiology.
[7] C. Jung,et al. Experiences on conversion to once-daily Advagraf and sirolimus combination in stable kidney recipients. , 2014, Transplantation proceedings.
[8] Eberechukwu Onukwugha,et al. Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer , 2014, BMC Medical Research Methodology.
[9] C. Kyriakopoulos,et al. Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison , 2014, Clinical Medicine Insights. Oncology.
[10] Lois Lamerato,et al. Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems , 2013, Supportive Care in Cancer.
[11] I Syndikus,et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.
[12] F. Saad,et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. , 2012, The Lancet. Oncology.
[13] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.
[14] M. Pino,et al. A Changing Landscape in Castration-Resistant Prostate Cancer Treatment , 2012, Front. Endocrin..
[15] M L Kilgore,et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006 , 2011, Prostate Cancer and Prostatic Diseases.
[16] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[17] K. Tomer,et al. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. , 2011, Cancer research.
[18] J. Machiels,et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.
[19] P. Kantoff,et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.
[20] P. Nelson,et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.
[21] M. Shulman,et al. The natural history of androgen independent prostate cancer. , 2004, The Journal of urology.
[22] H. Moch,et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. , 2000, Human pathology.
[23] A W Partin,et al. Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.
[24] W. Lowrance,et al. Castration-resistant prostate cancer: AUA guideline amendment. , 2015, The Journal of urology.
[25] M. Nørgaard,et al. Clinical Epidemiology Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article , 2022 .